Search Medical Condition
Please enter condition
Please choose location

Bergisch-Gladbach, Germany Clinical Trials

A listing of Bergisch-Gladbach, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (186) clinical trials

Hemopatch Performance Evaluation: A Prospective Observational Registry

To assess the clinical performance and safety of HEMOPATCH Sealing Hemostat in a post-marketing setting in cardiovascular, thoracic, urologic, neurological, and other general surgical procedures.

Phase N/A

0.0 miles

Learn More »

Study of Olaparib (Lynparza ) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

This is a prospective, multicenter, randomized, open-label, phase 3 trial evaluating the efficacy and safety of olaparib versus enzalutamide or abiraterone in subjects with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior treatment with a new hormonal agent (NHA) and have a qualifying tumor mutation in one of 15 ...

Phase

1.54 miles

Learn More »

Short-term Preoperative Treatment With Enzalutamide Alone or in Combination With Exemestane in Primary Breast Cancer

This study is being carried out to see if the antiandrogen enzalutamide has antitumour effects in early breast cancer. Enzalutamide blocks the action of androgens on the androgen receptor (AR) and may slow down or stop breast cancers growing. Enzalutamide is approved for the treatment of prostate cancer. The trial ...

Phase

1.54 miles

Learn More »

Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer

OBJECTIVES: Primary - Compare the disease-free survival rate in women with stage III breast cancer treated with adjuvant chemotherapy with vs without darbepoetin alfa. Secondary - Compare local recurrence and overall survival in patients receiving these regimens. - Compare toxicity of these regimens in these patients. - Compare quality of ...

Phase N/A

1.54 miles

Learn More »

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice

Postmarketing Observational Study to Evaluate the Work Productivity, Safety and Efficacy of Humira for the Treatment of Moderate to Severe Plaque Psoriasis in Daily Clinical Practice. The primary objectives of the PMOS are to explore changes in health related care utilization data by the evaluation of: the number of missed ...

Phase N/A

1.54 miles

Learn More »

Dimethyl Fumarate (DMF) Observational Study

Patients aged 12 to under 18 may be included where enrollment of pediatric patients in this study is considered observational and is permissible by local regulations.

Phase N/A

3.62 miles

Learn More »

Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry

This is a prospective registry allowing a structured, non-interventional collection of data. Participating physicians will not be subject to any instructions with regard to the diagnosis and therapy of their patients. All patient treatment is carried out within clinical routine, at the discretion of the physician and according to existing ...

Phase N/A

3.62 miles

Learn More »

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)

This is a Phase III clinical study to investigate the efficacy and safety of FP-1201-lyo (recombinant human interferon [IFN] beta-1a) compared to placebo in patients diagnosed with moderate or severe acute respiratory distress syndrome (ARDS). Primary objective is to demonstrate the efficacy of FP-1201-lyo in improving the clinical course and ...

Phase

4.21 miles

Learn More »

Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC

The aim of this study is to demonstrate that OSE2101 (Arm A) is superior to standard chemotherapy, pemetrexed or docetaxel (Arm B), in prolonging overall survival (OS) in HLA-A2 positive patients with locally advanced (IIIB) or metastatic NSCLC as 2nd line therapy after failure of prior platinum-based chemotherapy or 3rd ...

Phase

4.21 miles

Learn More »

Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy

Parkinson's disease (PD) is the second most common neurodegenerative disorder in the world. It can be treated sufficiently until motor complications with fluctuations of mobility and dyskinesia develop. The quality of life is relentlessly deteriorating with longer disease duration once the complications of conservative oral therapy develop. Continuous dopaminergic stimulation ...

Phase N/A

4.21 miles

Learn More »